Connor, Clark & Lunn Investment Management Ltd. Supernus Pharmaceuticals, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $21.1 Billion
- Q1 2025
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 172,259 shares of SUPN stock, worth $5.46 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
172,259
Previous 201,569
14.54%
Holding current value
$5.46 Million
Previous $7.29 Million
22.6%
% of portfolio
0.03%
Previous 0.04%
Shares
10 transactions
Others Institutions Holding SUPN
# of Institutions
305Shares Held
60.8MCall Options Held
8.8KPut Options Held
6.3K-
Black Rock Inc. New York, NY10.4MShares$329 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.16MShares$195 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.2MShares$165 Million2.59% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.9MShares$92 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.7MShares$85.6 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.7B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...